News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
FDA Sends Closeout Letter to Cephazone
June 29, 2012
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
The FDA has sent a closeout to Cephazone Pharma after an inspection of changes made since last year’s warning letter.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
MORE ON THIS TOPIC
Insights
Australia’s clinical trial advantage gains ground amid U.S. uncertainty
October 26, 2026
·
4 min read
·
Jennifer C. Smith-Parker
Policy
Roche flags ‘final opportunity’ for Germany to reestablish as a reliable investment location
October 23, 2026
·
2 min read
·
Nick Paul Taylor
FDA
FDA uncages Aardvark’s Prader-Willi study after new data cleared safety concerns
October 23, 2026
·
3 min read
·
Tristan Manalac
FDA
Biohaven shares pop as FDA accepts resubmission for ataxia drug with adcomm expected
October 22, 2026
·
2 min read
·
Heather McKenzie
